Your browser doesn't support javascript.
loading
Temporary Delayed Hypersensitivity Reaction to Botulinum Toxin-A After COVID-19 Vaccination: A Case Series.
Padilla-Pantoja, Fabio Daniel; Fakih-Gomez, Nabil; Muñoz-Gonzalez, Cristina; Prazeres, Sandra; Galindo-Ferreiro, Alicia.
Afiliación
  • Padilla-Pantoja FD; Department of Ophthalmology, Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain.
  • Fakih-Gomez N; Department of Facial Plastic & Cranio-Maxillo-Facial Surgery, Fakih Hospital, Khaizaran, Lebanon.
  • Muñoz-Gonzalez C; Department of Facial Plastic & Cranio-Maxillo-Facial Surgery, Fakih Hospital, Khaizaran, Lebanon.
  • Prazeres S; Department of Ophthalmology, Hospital CUF Porto, Porto, Portugal.
  • Galindo-Ferreiro A; Department of Ophthalmology, Hospital Universitario Rio Hortega, C/Dulzaina 2, 47012, Valladolid, Spain. ali_galindo@yahoo.es.
Aesthetic Plast Surg ; 2024 Jul 24.
Article en En | MEDLINE | ID: mdl-39046483
ABSTRACT

PURPOSE:

The occurrence of a hypersensitivity reaction with the injection of botulinum toxin type A (BTX-A) in cosmetic use is a rare complication. We report the largest case series of temporary delayed hypersensitivity reaction (DHR) with BTX-A following COVID-19 vaccination and the first cases to incobotulinum toxin A (incoBTX-A).

METHODS:

A retrospective multicentric case series of patients who developed a DHR to BTX-A after COVID-19 vaccination.

RESULTS:

Twelve patients were treated with BTX-A injections for the management of facial rhytids. The age range was between 29 and 45 years. Ten (83.3%) were female. Ten (83.3%) patients received incoBTX-A, and two received onabotulinum toxin A (onaBTX-A). All patients had COVID-19 vaccination (mRNA vaccine) between 1 and 7 months before. Within an average time of 24 h after BTX-A injection, all patients developed progressive facial swelling and erythema that were more prominent at the injection points. Intradermal allergic tests to BTX-A were performed in six (50%) patients, and the results were all negative. Adequate clinical control was achieved with systemic corticosteroids and antihistamines. After 1 year with no further vaccination, a new BTX-A treatment (provocation test) was performed in all patients with no secondary effects.

CONCLUSION:

Previous COVID-19 vaccination and the absence of new adverse events with further BTX-A injections suggest a temporary DHR. Clinicians should be aware of the importance of immunization history and its potential post-vaccine immunogenic effects with BTX-A. LEVEL OF EVIDENCE IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Aesthetic Plast Surg Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Aesthetic Plast Surg Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos